Business News Agency reported on January 6th yesterday that the State Food and Drug Administration announced that it would treat compound preparations containing ephedrine (excluding Chinese proprietary Chinese medicines containing ephedra), oral solution containing codeine, and fenoxantole compound preparations. Such electronic compound preparations containing special drugs are used for electronic supervision to further strengthen drug management and prevent the loss and abuse of drugs from medicinal sources.

Combining oral solution containing codeine is a commonly used antitussive drug for the general public. Once used in large doses, it can easily lead to abuse of addiction. Compounds containing ephedrine and fenone ester-containing compound are prone to influx into illegal channels. In the extraction of ephedrine to produce methamphetamine and so on.

According to the State Food and Drug Administration, companies that produce compound preparations containing ephedrine, oral compound solutions containing codeine, and fenone ester-containing compound preparations should join the electronic drug regulatory network before December 31, 2011. , It is required to add (paste) uniform electronic identification monitoring codes to the minimum sales package of listed products according to the regulations, and to do a good job of network access, endowment and nuclear injection verification work according to the requirements of the State Bureau.

From January 1, 2012 onwards, all products that contain ephedrine-based compound preparations, codeine-containing compound oral solutions, and diphenoxylate-containing compound preparations, unbranded and unused electronic surveillance codes will not be sold.